RS54791B1 - Oralni sastav molsidomina sa produženim oslobađanjem za aterosklerozu - Google Patents
Oralni sastav molsidomina sa produženim oslobađanjem za aterosklerozuInfo
- Publication number
- RS54791B1 RS54791B1 RS20160307A RSP20160307A RS54791B1 RS 54791 B1 RS54791 B1 RS 54791B1 RS 20160307 A RS20160307 A RS 20160307A RS P20160307 A RSP20160307 A RS P20160307A RS 54791 B1 RS54791 B1 RS 54791B1
- Authority
- RS
- Serbia
- Prior art keywords
- molsidomine
- hours
- released
- composition
- molsidomine released
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Upotreba molsidomina ili jedne od njegovih farmaceutski prihvatljive soli, u obliku oralnog čvrstog sastava sa odloženim dejstvom delotvornim tokom 24 sata, za pravljenje leka namenjenog prevenciji ili ublažavanju razvoja ateroskleroza, u kojoj pomenuti sastav predstavlja nivo rastvora in vitro, meren spektrofotometrijski na 286 ili 311 nm u skladu sa metodom opisanom u Evropskoj farmakopeji, trećem izdanju (ili U.S.P. XXIV) od 50 t.p.m. u 500 ml u rastvoru HCl 0,1 N, na 37°C, od :- 15 do 25 % molsidomina oslobođenog posle sat vremena- 20 do 35 % molsidomina oslobođenog posle 2 sata- 50 do 65 % molsidomina oslobođenog posle 6 sati- 75 do 95 % molsidomina oslobođenog posle 12 sati- > 85 % molsidomina oslobođenog posle 18 sati- > 90 % molsidomina oslobođenog posle 24 sati,Plazmatksi vrh molsidomina dobijen in vivo se pokazuje za 2,5 do 5 sati, posebno za 3-4sata, posle davanja pomenutog oblika i imao je vrednost između 25 i 40 ng/ml plazme, u kojoj čvrsti oralni sastav napred spomenut sadrži, po jedinici doziranja namenjene da bude davana dnevno, između 14 i 24 mg molsidomina, i u kojoj je tretman u trajanju od bar 6 meseci.Prijava sadrži još 2 patentna zahteva.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0403534A FR2868314B1 (fr) | 2004-04-05 | 2004-04-05 | Nouvelle utilisation therapeutique de la molsidomine et de ses sels pharmaceutiquement acceptables |
| PCT/EP2005/003531 WO2005107761A1 (fr) | 2004-04-05 | 2005-04-01 | Composition orale de la molsidomine a liberation prolongee pour le traitement de l’atherosclerose |
| EP05755780.3A EP1732565B8 (fr) | 2004-04-05 | 2005-04-01 | Composition orale de la molsidomine a liberation prolongee pour le traitement de l"atherosclerose |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS54791B1 true RS54791B1 (sr) | 2016-10-31 |
Family
ID=34944920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20160307A RS54791B1 (sr) | 2004-04-05 | 2005-04-01 | Oralni sastav molsidomina sa produženim oslobađanjem za aterosklerozu |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US7754715B2 (sr) |
| EP (1) | EP1732565B8 (sr) |
| JP (1) | JP5117847B2 (sr) |
| KR (1) | KR101162385B1 (sr) |
| CN (1) | CN1938032B (sr) |
| AU (1) | AU2005239799B2 (sr) |
| BE (1) | BE1016580A3 (sr) |
| BR (1) | BRPI0509642A (sr) |
| CA (1) | CA2562287C (sr) |
| CY (1) | CY1117614T1 (sr) |
| DK (1) | DK1732565T3 (sr) |
| ES (1) | ES2567576T3 (sr) |
| FR (1) | FR2868314B1 (sr) |
| HK (1) | HK1092736A1 (sr) |
| HR (1) | HRP20160479T1 (sr) |
| HU (1) | HUE029199T2 (sr) |
| IL (1) | IL178440A0 (sr) |
| IT (1) | ITTO20050220A1 (sr) |
| MA (1) | MA28518B1 (sr) |
| MD (1) | MD4080C1 (sr) |
| NO (1) | NO336913B1 (sr) |
| NZ (1) | NZ550341A (sr) |
| PL (1) | PL1732565T3 (sr) |
| RS (1) | RS54791B1 (sr) |
| RU (1) | RU2388475C2 (sr) |
| SI (1) | SI1732565T1 (sr) |
| UA (1) | UA88461C2 (sr) |
| WO (1) | WO2005107761A1 (sr) |
| ZA (1) | ZA200608219B (sr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2668947B1 (en) * | 2012-05-31 | 2016-11-30 | G. Pohl-Boskamp GmbH & Co. KG | Induction of arteriogenesis with a nitric oxide-donor such as nitroglycerin |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5385937A (en) * | 1991-04-10 | 1995-01-31 | Brigham & Women's Hospital | Nitrosation of homocysteine as a method for treating homocysteinemia |
| FR2805462B1 (fr) * | 2000-02-24 | 2003-08-15 | Therabel Res | Nouvelle forme galenique orale a liberation prolongee de la molsidomine |
| US6472390B1 (en) * | 2001-11-13 | 2002-10-29 | Duke University | Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure |
| KR100464876B1 (ko) * | 2001-11-15 | 2005-01-06 | 학교법인 인제학원 | 동충하초의 코르디세핀을 함유하는 항혈전제 조성물 |
| WO2010062256A1 (en) * | 2008-11-27 | 2010-06-03 | Nanyang Polytechnic | Process and system for automatic identification of the larvae of aedes albopictus and aedes aegypti |
-
2004
- 2004-04-05 FR FR0403534A patent/FR2868314B1/fr not_active Expired - Lifetime
-
2005
- 2005-04-01 BR BRPI0509642-1A patent/BRPI0509642A/pt not_active Application Discontinuation
- 2005-04-01 CN CN2005800107845A patent/CN1938032B/zh active Active
- 2005-04-01 RU RU2006134695/15A patent/RU2388475C2/ru active
- 2005-04-01 UA UAA200610515A patent/UA88461C2/ru unknown
- 2005-04-01 WO PCT/EP2005/003531 patent/WO2005107761A1/fr active Application Filing
- 2005-04-01 EP EP05755780.3A patent/EP1732565B8/fr active Active
- 2005-04-01 ZA ZA200608219A patent/ZA200608219B/xx unknown
- 2005-04-01 KR KR1020067020582A patent/KR101162385B1/ko active IP Right Grant
- 2005-04-01 RS RS20160307A patent/RS54791B1/sr unknown
- 2005-04-01 ES ES05755780.3T patent/ES2567576T3/es active Active
- 2005-04-01 NZ NZ550341A patent/NZ550341A/en unknown
- 2005-04-01 US US10/599,634 patent/US7754715B2/en active Active
- 2005-04-01 JP JP2007506708A patent/JP5117847B2/ja active Active
- 2005-04-01 MD MDA20060241A patent/MD4080C1/ro active IP Right Grant
- 2005-04-01 AU AU2005239799A patent/AU2005239799B2/en active Active
- 2005-04-01 SI SI200532067A patent/SI1732565T1/sl unknown
- 2005-04-01 CA CA2562287A patent/CA2562287C/fr active Active
- 2005-04-01 DK DK05755780.3T patent/DK1732565T3/en active
- 2005-04-01 PL PL05755780T patent/PL1732565T3/pl unknown
- 2005-04-01 HU HUE05755780A patent/HUE029199T2/en unknown
- 2005-04-04 IT IT000220A patent/ITTO20050220A1/it unknown
- 2005-04-04 BE BE2005/0173A patent/BE1016580A3/fr active
-
2006
- 2006-10-02 MA MA29367A patent/MA28518B1/fr unknown
- 2006-10-04 IL IL178440A patent/IL178440A0/en active IP Right Grant
- 2006-10-04 NO NO20064510A patent/NO336913B1/no unknown
-
2007
- 2007-01-02 HK HK07100028.9A patent/HK1092736A1/zh unknown
-
2016
- 2016-05-04 HR HRP20160479TT patent/HRP20160479T1/hr unknown
- 2016-06-02 CY CY20161100486T patent/CY1117614T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA94916C2 (ru) | Композиция тразодона для введения один раз в день | |
| CL2008001966A1 (es) | Composicion de disolucion oral que comprende lamotrigina,en forma de particulas con lamotrigina recubiertas con una capa para enmascarar el sabor y granulos que comprenden un desinfectante y un alcohol de azucar y/o un hidrato de carbono; metodo de preparacion;uso para tratar trastornos del humor y prevencion de ataques. | |
| HK1057899A1 (en) | Arylmethylamine derivatives for use as tryptase inhibitors | |
| HK1115070A1 (en) | Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms | |
| HK1087702A1 (en) | Arylmethylamine derivatives for use as tryptase inhibitors | |
| EA200900264A1 (ru) | Композиции флибансерина и способ их приготовления | |
| ME00347B (me) | Dozirani oblik pramipeksola za upotrebu jedanput dnevno | |
| HRP20130892T1 (hr) | Farmaceutske formulacije i njihove upotrebe u lijeäśenju ženske seksualne disfunkcije | |
| MX2009001711A (es) | Formulaciones de liberacion sostenida de topiramato. | |
| Tuite et al. | Recent developments in the pharmacological treatment of Parkinson’s disease | |
| RS20080430A (en) | Antibiotic compositions of modified release and process of production thereof | |
| NO20080827L (no) | Faste doseringsformuleringer av narkotiske legemidler som har forbedret bukal adsorpsjon | |
| TNSN08018A1 (en) | Novel pharmaceutical modified release dosage form cyclooxygenase enzyme inhibitor | |
| AR045289A1 (es) | Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento | |
| RS54050B1 (sr) | Formulacije i metode za lečenje amiloidoze | |
| JP2012502047A5 (sr) | ||
| AR046410A1 (es) | Composiciones farmaceuticas para la liberacion modificada de modafinilo | |
| SV2002000036A (es) | Inhibidores de acido abierto y sales de dihidroxilo de reductasa hmg-co-a ref.b.11111/rm/ma | |
| RS54791B1 (sr) | Oralni sastav molsidomina sa produženim oslobađanjem za aterosklerozu | |
| EE200200472A (et) | Molsidomiini pikendatud vabanemisega suukaudse manustamisega galeeniline ravimvorm | |
| BRPI0506710A (pt) | composições farmacêuticas de liberação controlada | |
| NO20092654L (no) | Anvendelse av forbindelse | |
| ES2550790T3 (es) | Agente terapéutico para el dolor producido por cáncer |